tag:blogger.com,1999:blog-33960805.post4163022466133695413..comments2023-10-30T02:03:47.513-07:00Comments on Clinical Psychology and Psychiatry: A Closer Look: Key Opinion Leader Provides False Information in Psychiatry CMECL Psychhttp://www.blogger.com/profile/13990549972520745769noreply@blogger.comBlogger3125tag:blogger.com,1999:blog-33960805.post-53551291494299234332009-03-13T11:24:00.000-07:002009-03-13T11:24:00.000-07:00I have a concern with the vague statement of the s...I have a concern with the vague statement of the sexual side effects of risperdal. Ex.,increased sexual desires...in what age range,gender,ethnicity, etc.? Furthermore, how does this effect children who have been on risperdal at such ages as 6,7,8 and so on? Does it throw them into puberty before the natural order? In puberty, does it make the sexual development more aggressive?<BR/>If all of this is going on and no studies have been done or clearly defined this issue, then why are they giving risperdal to children when the side effects could cause severe damage to not only the children but to society?Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-33960805.post-87210813112798945672007-12-22T12:46:00.000-08:002007-12-22T12:46:00.000-08:00See also this article from the New York Times:Undi...See also this article from the <I>New York Times</I>:<BR/><BR/><B>Undisclosed Financial Ties Prompt Reproval of Doctor</B><BR/><BR/>By Melody Petersen<BR/>Published: August 3, 2003<BR/><BR/>Two scientists are raising concerns about an article in a medical journal that described experimental treatments for depression because an author did not disclose his significant financial ties to three therapies that he mentioned favorably.<BR/><BR/>The executive editor of the journal said it had not required disclosure of the potential conflicts, but was considering changing its policy in light of the criticism. The ties between pharmaceutical companies and researchers have come under increasing scrutiny in recent years.<BR/><BR/>The lead author of the article, <B>Dr. Charles B. Nemeroff</B>, chairman of the department of psychiatry and behavioral sciences at the Emory School of Medicine in Atlanta, said he would have reported the conflicts of interest, which include owning the patent on a treatment he mentioned, if the journal had asked him to. <BR/><BR/>[rest of article snipped]<BR/><BR/>Read the full text <A HREF="http://query.nytimes.com/gst/fullpage.html?sec=health&res=9407E7DE103EF930A3575BC0A9659C8B63" REL="nofollow">here</A>.Alex Chernavskyhttps://www.blogger.com/profile/08200015595839585212noreply@blogger.comtag:blogger.com,1999:blog-33960805.post-80898971556597062022007-12-13T16:03:00.000-08:002007-12-13T16:03:00.000-08:00I've read a posting by a shrink accusing Nemeroff ...I've read a posting by a shrink accusing Nemeroff of crafting "lore" that luvox had less sexual side-effects than the other SSRIs. He smells like a repeat offender.<BR/><BR/>The <B>lore</B> that fluvoxamine has a lower incidence comes from Nemeroff et al. Depression 3: 163-169, l995. In a double-blind comparison, "Significantly more patients reported sexual dysfunction in the sertraline (28%) than in the fluvoxamine (10%) group." It was not clear if sexual function was evaluated by specific questioning. The party line from Solvay to me in a letter dated 2/7/97 was, "Reaching definitive comparative conclusions regarding SSRIs and incident rates of side effects is difficult... Overall, SSRIs cause significantly less sexual dysfunction than tricyclic antidepressants."<BR/><BR/>http://www.dr-bob.org/tips/split/SSRI-sexual-dysfunction.htmlAnonymousnoreply@blogger.com